Results 141 to 150 of about 22,145 (200)

Targeting SLC5A2 suppresses colorectal tumour development by enhancing NK cell activity through extracellular vesicle-dependent MICA/B signalling. [PDF]

Clin Transl Med
Xiao J, Wu J, Deng F, Liu C, Chen Y, Shen K, Wang C, Lin W, Liu W, Ning Z, Zhou R, Zhao L.   +11 more
europepmc   +1 more source

NKG2D CAR-T cells for solid tumor immunotherapy: advances, challenges, and future directions. [PDF]

Front Immunol
Liu C, Wang Z, Zhang W, Cheng G, Cheng S, Qin L, Ye H, Ren W.   +7 more
europepmc   +1 more source

cGAS/STING-mediated upregulation of NKG2D ligands in LSCs contributes to enhanced sensitivity to NK cells. [PDF]

Front Oncol
Ouyang Y, Qin Y, Zhang Q, Zhu P, Zhu H.
europepmc   +1 more source

Research progress on the role and dysregulation of NK cells in anti-tuberculosis immunity. [PDF]

Front Immunol
Zheng Y, Li F, Zhang B, Wang X, Jiao Z, Wu X, Yang T, Deng J, Xiong Y, Huang Z, Huang J.   +10 more
europepmc   +1 more source

Targeting endosomal trafficking-mediated antigen escape to resensitize myeloma to CAR-T therapy. [PDF]

J Immunother Cancer
Wang Z, Wang G, Liu Y, Zhao Y, Guo S, Yang Y, Zhang Q, Hu C, Chang S, Wu X, An D, Hu H, Cai H, Zhang L, Shi J.   +14 more
europepmc   +1 more source

NKG2D Ligands in Cancer

, 2018
openaire   +1 more source